Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

AstraZeneca recently announced positive toplined interim results from SERENA-6, a randomised, multicentre, double-blind Phase ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

March 11 (Reuters) - Pfizer (PFE.N), opens new tab and Arvinas' (ARVN.O), opens new tab experimental treatment failed to delay progression of breast cancer in patients with most common type of the ...

Pfizer and Arvinas’ estrogen receptor (ER ... med Faslodex in 624 patients with ER+/HER2- advanced or metastatic breast cancer who had already tried CDK 4/6 inhibitors and endocrine therapy.

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...